- Home
- CHPT vs THRD Comparison
CHPT vs THRD Comparison
Compare CHPT & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- THRD
- Stock Information
- Founded
- CHPT 2007
- THRD 2019
- Country
- CHPT United States
- THRD United States
- Employees
- CHPT N/A
- THRD N/A
- Industry
- CHPT Industrial Specialties
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- CHPT Consumer Discretionary
- THRD Health Care
- Exchange
- CHPT Nasdaq
- THRD Nasdaq
- Market Cap
- CHPT 483.4M
- THRD 513.2M
- IPO Year
- CHPT N/A
- THRD 2022
- Fundamental
- Price
- CHPT $1.14
- THRD $11.45
- Analyst Decision
- CHPT Hold
- THRD Strong Buy
- Analyst Count
- CHPT 15
- THRD 3
- Target Price
- CHPT $2.47
- THRD $20.33
- AVG Volume (30 Days)
- CHPT 13.0M
- THRD 218.2K
- Earning Date
- CHPT 12-04-2024
- THRD 11-07-2024
- Dividend Yield
- CHPT N/A
- THRD N/A
- EPS Growth
- CHPT N/A
- THRD N/A
- EPS
- CHPT N/A
- THRD N/A
- Revenue
- CHPT $441,698,000.00
- THRD N/A
- Revenue This Year
- CHPT N/A
- THRD N/A
- Revenue Next Year
- CHPT $23.54
- THRD N/A
- P/E Ratio
- CHPT N/A
- THRD N/A
- Revenue Growth
- CHPT N/A
- THRD N/A
- 52 Week Low
- CHPT $1.05
- THRD $7.08
- 52 Week High
- CHPT $3.13
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- CHPT 42.86
- THRD 40.06
- Support Level
- CHPT $1.08
- THRD $10.10
- Resistance Level
- CHPT $1.15
- THRD $12.49
- Average True Range (ATR)
- CHPT 0.08
- THRD 1.30
- MACD
- CHPT -0.00
- THRD -0.32
- Stochastic Oscillator
- CHPT 25.71
- THRD 25.00
About CHPT ChargePoint Holdings Inc.
ChargePoint designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.